104 patents
Page 4 of 6
Utility
External Ankle Brace
30 Sep 21
An external ankle brace is provided with a rigid heel enclosure for receiving the heel of the shoe, a lateral and medial sidewall for surrounding the sides of the shoe, a lateral and medial upright extension for housing the lower leg of the user, a lower fastening system for connecting the lateral and medial sidewalls underneath the sole of the shoe, and an upper fastening system for connecting the lateral and medial sidewall across the top of the shoe.
Mike W. Bean
Filed: 9 Jun 21
Utility
Antibiotic Conjugates
9 Sep 21
Marvin J. MILLER, Rui LIU, Patricia MILLER, Sergei VAKULENKO, Nichole K. STEWART, William BOGGESS
Filed: 9 Aug 18
Utility
HSP90 Beta Selective Inhibitors
2 Sep 21
Described are compounds of formula (I), based on an isoquinolin-1(2H)-one backbone, that function as Hsp90β selective inhibitors.
Brian Blagg, Sanket Mishra
Filed: 30 May 19
Utility
Phage Mimicking Nanoparticles
19 Aug 21
An antibacterial nanoparticle (ANP) and related methods and antibacterial medical products are disclosed.
Prakash Daniel Nallathamby, Juliane Hopf
Filed: 7 Nov 19
Utility
Plasma Injection Modules
12 Aug 21
A plasma injection module includes a fuel receiving end, a discharge end opposite the fuel receiving end, and an axial fluid pathway extending between the fuel receiving end and the discharge end.
Sergey B. Leonov
Filed: 10 Feb 21
Utility
Catalytic Hydrogel Membrane Reactor for Treatment of Aqueous Contaminants
29 Jul 21
Provided are catalytic assemblies which include a hollow fiber membrane permeable to a gas; a reactive coating permeable to the gas and a contaminant; and a plurality of catalytic nanoparticles embedded in the reactive coating adapted to catalyze a reaction between the gas and the contaminant.
Kyle Doudrick, Robert Nerenberg, Randal Marks
Filed: 8 Nov 19
Utility
Benzyl Amine-containing Heterocyclic Compounds and Compositions Useful Against Mycobacterial Infection
1 Jul 21
Described herein are compounds and compositions, and methods of making and their use as effective agents against mycobacterial infections.
Marvin J. MILLER, Garrett C. MORASKI
Filed: 28 Dec 20
Utility
Security for Wireless Communications
1 Jul 21
Devices and techniques for authenticating wireless communications are disclosed.
Thomas G. Pratt, Joseph Lawrence Loof, Eric Jesse
Filed: 19 Jun 19
Utility
Super-sensitivity Multiphoton Frequency-domain Fluorescence Lifetime Imaging Microscopy
24 Jun 21
One aspect of the present disclosure relates to systems and methods that can be used for super-sensitivity multiphoton frequency-domain fluorescence lifetime imaging microscopy (MPM-FD-FLIM).
Scott Howard, Genevieve Vigil, Yide ZHANG
Filed: 10 Mar 17
Utility
Method and Apparatus of Plasma Flow Control for Drag Reduction
3 Jun 21
A plasma plate is used to minimize drag of a fluid flow over an exposed surface.
Thomas C. Corke, Flint O. Thomas
Filed: 27 Dec 19
Utility
Frequency Domain Diffuse Optical Spectroscopy Device and Optical Detector Calibration Method
3 Jun 21
A frequency domain diffuse optical spectroscopy (FD-DOS) device and calibration method.
Roy A. Stillwell, Vincent James Kitsmiller, Thomas D. O'Sullivan
Filed: 5 Apr 19
Utility
Refillable Drug Delivery by Affinity Homing
27 May 21
Described herein are compositions and methods for a novel drug delivery platform using affinity homing.
Matthew J. Webber, Lei Zou
Filed: 5 Apr 19
Utility
Nanoallergens and Uses Thereof
13 May 21
Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle.
Zihni Basar BILGICER, Peter Edward DEAK, Tanyel KIZILTEPE BILGICER, Jared Francis STEFANICK, Jonathan Darryl ASHLEY
Filed: 18 Dec 20
Utility
Systems and Methods for Designing Synthetic Antimicrobial Peptides
6 May 21
Methods for generating synthetic antimicrobial peptides include (i) identifying a peptide fragment of an antimicrobial peptide that includes a cluster of cationic residues and at least about 25% hydrophobic residues, preferably between about 40%-60% hydrophobic residues and (ii) generating a peptide variant library based on the peptide fragment by varying a hydrophobicity and charge of residues that make up the peptide fragment.
Francisco R. Fields, Shaun W. Lee
Filed: 1 Jun 18
Utility
Polymer/exfoliated Nano-composite Films with Superior Mechanical Properties
29 Apr 21
Nano-composite films and methods for their fabrication.
Yunsong Pang, Tengfei Luo
Filed: 2 Jul 19
Utility
Covalent Heterobivalent Antibody Inhibitors and Ligands
22 Apr 21
The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment.
Zihni Basar BILGICER, Peter Edward DEAK, Tanyel KIZILTEPE BILGICER, Michael William HANDLOGTEN, Jonathan Darryl ASHLEY
Filed: 18 Dec 20
Utility
Novel Method of Catalyst Preparation by Pressure Dilution
22 Apr 21
Described is a method for the preparation of a reforming catalyst.
Eduardo Wolf, Vardan Danghyan
Filed: 4 Jun 18
Utility
Non-volatile Multi-level Cell Memory Using a Ferroelectric Superlattice and Related Systems
1 Apr 21
An N-bit non-volatile multi-level memory cell (MLC) can include a lower electrode and an upper electrode spaced above the lower electrode.
Kai Ni, Suman Datta, Andrew Kummel
Filed: 25 Sep 20
Utility
Additive Manufacturing Device For Biomaterials
25 Mar 21
An additive manufacturing (AM) device for biomaterials comprises a reservoir, a shaft, and a material delivery head.
David J. Hoelzle
Filed: 3 Dec 20
Utility
Systems and Methods for Assessing Colorectal Cancer Molecular Subtype and Risk of Recurrence and for Determining and Administering Treatment Protocols Based Thereon
18 Mar 21
Products, systems, and methods for classifying human colorectal cancer into a consensus molecular subtype (CMS) and for assessing risk of recurrence based on CMS scores and based on risk scores derived from abbreviated gene expression profiles, for determining suitable treatment protocols for human colorectal cancer patients based on the determined CMS classification and based on the determined risk of recurrence, and for administering the suitable treatment protocols.
Steven Buechler
Filed: 7 Mar 19